Funding for this research was provided by:
Received: 17 June 2021
Accepted: 17 August 2021
First Online: 14 September 2021
: The PETAL trial (ClinicalTrials.gov NCT00554164; EudraCT 2006-001641-33) was a multicenter study for newly diagnosed aggressive non-Hodgkin lymphomas. The study was approved by the Federal Institute for Drugs and Medical Devices and the ethics committees of all participating sites. All patients gave written informed consent including their permission to use their data for post-hoc scientific analyses.
: UD received institutional research grants and honoraria from Amgen Germany and Roche Pharma. No other potential conflicts of interest relevant to this article exist.